Literature DB >> 25665723

Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments.

Carla Treloar1, Clair Jackson1, Rebecca Gray1, Jamee Newland1, Hannah Wilson1, Veronica Saunders1, Priscilla Johnson1, Loren Brener1.   

Abstract

INTRODUCTION: Despite Aboriginal Australians being over-represented in populations of people living with hepatitis C (HCV), there is a dearth of research to guide policy and programme development in the area of care and treatment, particularly relating to new HCV treatments.
METHOD: In-depth interviews were conducted with 39 people identifying as Aboriginal Australians and living with HCV in New South Wales.
RESULTS: Participants' experiences were characterised by a lack of detailed or appropriate information provided at diagnosis, high levels of stigma associated with HCV and low overall knowledge of HCV as reported for themselves and their communities. Despite poor diagnosis experiences, participants had undertaken changes to their lifestyle, especially in relation to alcohol use, in order to promote liver health. Concerns about treatment side effects and efficacy impacted participants' decisions to undertake treatment. Eleven participants had undertaken HCV treatment in a variety of care models with a peer worker and in prison.
CONCLUSIONS: The similarities between concerns and experiences of Aboriginal people and other populations living with HCV do not suggest that services and strategies to engage these populations should also be the same. These results suggest that further engagement of the primary care sector in HCV care is important as well as increasing Aboriginal community knowledge of HCV. A variety of service models should be available to meet individuals' preferences, including those offered within Aboriginal community controlled health services emphasising holistic notions of health, and supported by information and communication programmes using principles of health literacy relevant to Aboriginal people.

Entities:  

Keywords:  Aboriginal; Australia; hepatitis C; treatment

Mesh:

Year:  2015        PMID: 25665723     DOI: 10.1080/13557858.2015.1004870

Source DB:  PubMed          Journal:  Ethn Health        ISSN: 1355-7858            Impact factor:   2.772


  4 in total

1.  Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.

Authors:  C Rodrigo; A A Eltahla; R A Bull; F Luciani; J Grebely; G J Dore; T Applegate; K Page; J Bruneau; M D Morris; A L Cox; W Osburn; A Y Kim; N H Shoukry; G M Lauer; L Maher; J Schinkel; M Prins; M Hellard; A R Lloyd
Journal:  J Viral Hepat       Date:  2016-11-03       Impact factor: 3.728

2.  Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention.

Authors:  Helen R Stagg; Julian Surey; Marie Francis; Jennifer MacLellan; Graham R Foster; André Charlett; Ibrahim Abubakar
Journal:  BMC Med       Date:  2019-04-01       Impact factor: 8.775

3.  Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.

Authors:  Joanne M Carson; Behzad Hajarizadeh; Josh Hanson; James O'Beirne; David Iser; Phillip Read; Anne Balcomb; Jane Davies; Joseph S Doyle; Jasmine Yee; Marianne Martinello; Philippa Marks; Gail V Matthews; Gregory J Dore
Journal:  J Viral Hepat       Date:  2022-05-18       Impact factor: 3.517

4.  Evaluation of the Deadly Liver Mob program: insights for roll-out and scale-up of a pilot program to engage Aboriginal Australians in hepatitis C and sexual health education, screening, and care.

Authors:  Carla Treloar; Max Hopwood; Elena Cama; Veronica Saunders; L Clair Jackson; Melinda Walker; Catriona Ooi; Ashley Ubrihien; James Ward
Journal:  Harm Reduct J       Date:  2018-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.